Login
Companies $UTHR
$587.88 +$0.00 (0.0%) After hours
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp

unither.com

What Do They Do?

Sells Tyvaso inhaled medicines for people with pulmonary hypertension, along with other medicines for pulmonary hypertension and high-risk neuroblastoma; develops technologies to expand transplantable organs.

How Do They Make Money?

Tyvaso is the largest business: specialty pharmaceutical distributors buy its inhaled medicines, and United Therapeutics is paid after shipment or delivery; distributor balances are generally due within 30 to 90 days.

revenue
SegmentShareRevenue
Tyvaso
Sold outright

59%
FY2022: 45%
Remodulin
Sold outright

17%
FY2022: 26%
Orenitram
Sold outright

16%
FY2022: 17%
Unituxin
Sold outright
7.1%
FY2022: 9.5%
Adcirca
Sold outright
0.9%
FY2022: 2.1%
Other
0.8%
FY2022: 0.7%

Who Are Their Customers?

In the U.S., specialty pharmaceutical distributors handle Tyvaso, Remodulin, the pumps and Orenitram; Cencora distributes Unituxin, while Adcirca moves through Lilly’s pharmaceutical wholesale network. International pharmaceutical distributors handle Nebulized Tyvaso, Remodulin and Unituxin.

Do Revenues Turn Into Profits?

Yes. It kept 42 cents of every revenue dollar as net income in FY2025 and turned 33 cents into free cash flow.

Operating income, FY2025
47% of revenue
▲ +8% vs FY2024 ($1.4B, 48%)
Net income, FY2025
42% of revenue
▲ +12% vs FY2024 ($1.2B, 42%)
Free cash flow, FY2025
33% of revenue
▼ −4% vs FY2024 ($1.1B, 38%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +4%
vs $799.5M in Q3 FY2025
Net income
▼ −24%
vs $338.7M in Q3 FY2025
Total Tyvaso share of revenue vs 59.8% in Q3 FY2025

Growing. Revenue grew 89% in 4 years, from $1.7B in FY2021 to $3.2B in FY2025, about 17% a year.

New Remodulin pump The older report describes development of another next-generation Remodulin delivery system; the latest report says the patient-filled RemunityPRO pump launched.

Revenue over time
Tyvaso Remodulin Orenitram Unituxin Adcirca Other
$5B$2.5B$0

Who Do They Compete With?

Competes with Merck

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support